These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 32622363)

  • 21. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    Kaneko M
    Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
    Huang XZ; Jia H; Xiao Q; Li RZ; Wang XS; Yin HY; Zhou X
    Front Oncol; 2020; 10():958. PubMed ID: 32612955
    [No Abstract]   [Full Text] [Related]  

  • 23. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    Li J; Li Q; Zhang L; Zhang S; Dai Y
    Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
    BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
    Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
    Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
    Zhang M; Yu X; Wang J; Li Y; Cao L
    J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
    Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
    Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
    Shao F; Duan Y; Zhao Y; Li Y; Liu J; Zhang C; He S
    Aging (Albany NY); 2021 Mar; 13(6):8975-8988. PubMed ID: 33705352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    Wu K; Liang J; Shao Y; Xiong S; Feng S; Li X
    Front Pharmacol; 2021; 12():777663. PubMed ID: 34975480
    [No Abstract]   [Full Text] [Related]  

  • 36. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Mirza MR; Pignata S; Ledermann JA
    Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
    Jiang X; Li X; Li W; Bai H; Zhang Z
    J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.